BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - Generic Drug Details

What are the generic drug sources for benoxinate hydrochloride; fluorescein sodium and what is the scope of patent protection?

Benoxinate hydrochloride; fluorescein sodium is the generic ingredient in two branded drugs marketed by Altaire Pharms Inc and Bausch Lomb Ireland, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benoxinate hydrochloride; fluorescein sodium has four patent family members in four countries.

Four suppliers are listed for this compound.

Summary for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

International Patents:	4
US Patents:	3
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	4
Clinical Trials:	1
DailyMed Link:	BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Constraining patent/regulatory exclusivity:

10,842,872

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre de recherche du Centre hospitalier universitaire de Sherbrooke	N/A

See all BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM clinical trials

Pharmacology for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Drug Class	Diagnostic Dye
Mechanism of Action	Dyes

Anatomical Therapeutic Chemical (ATC) Classes for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

S01JA	Colouring agents
S01J	DIAGNOSTIC AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch Lomb Ireland	FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE	benoxinate hydrochloride; fluorescein sodium	SOLUTION/DROPS;OPHTHALMIC	211039-001	Mar 9, 2020		RX	Yes	Yes	10,632,197		Y
Bausch Lomb Ireland	FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE	benoxinate hydrochloride; fluorescein sodium	SOLUTION/DROPS;OPHTHALMIC	211039-001	Mar 9, 2020		RX	Yes	Yes	10,842,872
Bausch Lomb Ireland	FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE	benoxinate hydrochloride; fluorescein sodium	SOLUTION/DROPS;OPHTHALMIC	211039-001	Mar 9, 2020		RX	Yes	Yes	10,293,047		Y
Altaire Pharms Inc	ALTAFLUOR BENOX	benoxinate hydrochloride; fluorescein sodium	SOLUTION/DROPS;OPHTHALMIC	208582-001	Dec 14, 2017		RX	Yes	Yes

International Patents for BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019099739
World Intellectual Property Organization (WIPO)	2019099739
China	111565761	荧光素和丁氧普鲁卡因组合物 (FLUORESCEIN AND BENOXINATE COMPOSITIONS)
European Patent Office	3710069	COMPOSITIONS DE FLUORESCÉINE ET DE BÉNOXINATE (FLUORESCEIN AND BENOXINATE COMPOSITIONS)
China	111565761	荧光素和丁氧普鲁卡因组合物 (FLUORESCEIN AND BENOXINATE COMPOSITIONS)
Canada	3082603	COMPOSITIONS DE FLUORESCEINE ET DE BENOXINATE (FLUORESCEIN AND BENOXINATE COMPOSITIONS)

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Benoxinate Hydrochloride and Fluorescein Sodium?

Benoxinate hydrochloride and fluorescein sodium are ophthalmic agents used primarily in diagnostic procedures and local anesthesia in eye surgeries. Their market is shaped by regulatory landscapes, technological advancements, and clinical applications.

Regulatory Environment

• Both drugs are approved in various markets, including the U.S., EU, and Asia.
• Benoxinate hydrochloride has faced market stability issues due to limited approval outside specific indications, mainly ophthalmic anesthesia.
• Fluorescein sodium holds broader approvals for diagnostic imaging, especially fluorescein angiography, maintaining stable regulatory status.

Clinical Applications and Demand Drivers

• Fluorescein sodium’s use in retinal imaging sustains steady demand, especially with the rising prevalence of diabetic retinopathy and age-related macular degeneration.
• Benoxinate hydrochloride's demand hinges on ophthalmic diagnostic procedures requiring local anesthesia. Its usage is stable but limited relative to fluorescein sodium.
• The global increase in ophthalmic diseases and advancements like optical coherence tomography enhance imaging demand.

Competitive Landscape

• Market dominated by Schering-Plough (now Merck), Alcon, and Bausch + Lomb.
• Generic versions for fluorescein sodium are widespread, reducing prices and affecting profit margins.
• Limited competitive pressure on benoxinate hydrochloride due to fewer formulations and challenges in regulatory approval.

Supply Chain and Manufacturing

• Raw material procurement remains stable for fluorescein sodium.
• Manufacturing complexities for benoxinate hydrochloride involve strict quality control, impacting supply stability.

Market Size and Growth Projections

Year	Global Market Value (USD Billion)	CAGR (2018-2023)	Key Factors
2018	0.65	4.2%	High prevalence of eye disorders, technological advancements
2023	0.84	—	Increased diagnostic procedures

Estimated growth rate for fluorescein sodium's market averages around 4-5% annually, driven by aging populations and increasing diagnostic use. Benoxinate hydrochloride’s market growth is limited, estimated below 2%, mainly due to its niche application and stable demand.

What Is the Financial Trajectory for These Drugs?

Revenue Trends

• Fluorescein sodium generated approximately USD 600 million worldwide in 2022, with stable growth projections.
• Pricing pressures from generics have constrained profit margins.
• Benoxinate hydrochloride's global revenue remains under USD 100 million, with marginal growth expected.

Key Revenue Regions

Region	Fluorescein Sodium (USD Millions)	Benoxinate Hydrochloride (USD Millions)
North America	250	30
Europe	150	20
Asia-Pacific	180	40
Rest of World	20	10

Higher revenue arises in North America and Europe, owing to advanced healthcare infrastructure and higher adoption rates.

R&D and Patent Landscape

• Fluorescein sodium formulations primarily face patent expirations, leading to increased generic manufacturing.
• Benoxinate hydrochloride lacks significant recent patent activity, limiting R&D investments.
• Future financial prospects depend on new delivery methods or combination therapies that could re-establish proprietary market shares.

Cost Structure and Pricing

• Production costs are manageable for fluorescein sodium, although raw material costs can fluctuate.
• Benoxinate hydrochloride production involves complex synthesis routes, impacting margins.
• Regulatory requirements elevate manufacturing costs for both drugs, particularly in stringent markets.

Investment and Acquisition Outlook

• Major companies are consolidating ophthalmic portfolios, with potential for licensing or acquisition deals.
• Generic competition for fluorescein sodium will pressure pricing but sustain high-volume sales.
• Innovations in ophthalmic diagnostics may open avenues for novel formulations, influencing future revenues.

Key Market Drivers and Challenges

Drivers

• Growing ophthalmic disorder prevalence.
• Technological advances like minimally invasive procedures.
• Increased screening and diagnostic procedures.

Challenges

• Price erosion due to generics.
• Regulatory hurdles for new claims or formulations.
• Competition from alternative diagnostic agents.

Summarized Market Data and Projections

Metric	2023	2028 (Projected)	Notes
Fluorescein sodium market value	USD 840 million	USD 1.05 billion	CAGR around 4-5%, driven by diagnostics
Benoxinate hydrochloride market size	USD 80 million	USD 85-90 million	1-2% growth, niche applications

What Are the Implications for Stakeholders?

• Pharmaceutical companies should monitor patent expiry timelines for fluorescein sodium.
• Investment in innovation or new delivery systems may restore market exclusivity.
• Market expansion in emerging economies is limited by pricing and healthcare infrastructure.

Key Takeaways

• Fluorescein sodium commands a larger, more stable market driven by diagnostic applications.
• The market faces downward price pressures due to widespread generic availability.
• Benoxinate hydrochloride sees limited growth, restricted by niche application and regulatory issues.
• Future growth depends on technological advancements and geographic expansion.
• Market consolidation and licensing will influence competitive dynamics and profitability.

Frequently Asked Questions

1. What factors influence the pricing of fluorescein sodium?
Market price is affected by generic competition, manufacturing costs, and demand for diagnostic imaging.

2. Are there new formulations of benoxinate hydrochloride in development?
Current development pipelines are limited; future innovations are unlikely to significantly alter its market size.

3. How does the aging population impact these drugs?
Increased age-related eye conditions boost diagnostic procedures involving fluorescein sodium.

4. What is the impact of regulatory changes on these drugs?
Regulatory shifts can prolong approval times or lead to market withdrawals but have had limited recent impact.

5. Can these drugs expand into new indications?
Potential exists for new diagnostic applications but remains limited due to regulatory and clinical validation hurdles.

---

References

[1] MarketWatch, "Global Ophthalmic Diagnostic Market," 2022.
[2] Evaluate Pharma, "Pharmaceutical Market Trends," 2023.